Physician profile
William E Prenatt
NPI 1316906191
$10,825.40
in general payments reported to CMS, 2019-2025
57 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $697 · 2021: $1,718 · 2022: $1,751 · 2023: $2,234 · 2024: $2,149 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,895.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,763.95 | 2019-2025 | |
| Ucb, INC. | $773.10 | 2021-2025 | Cimzia, Bimzelx |
| Novo Nordisk INC | $732.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $687.98 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $662.30 | 2019-2025 | Tepezza, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $630.16 | 2020-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $606.56 | 2022-2024 | Ingrezza |
| Viiv Healthcare Company | $363.06 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.80 | 2022-2024 | Caplyta |
| Lilly USA, LLC | $319.33 | 2019-2025 | Jardiance, Baqsimi, Lyumjev |
| Janssen Biotech, INC. | $285.23 | 2020-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $227.89 | 2024 | Voquezna |
| Radius Health, INC. | $193.89 | 2021-2025 | Tymlos |
| Daiichi Sankyo INC. | $173.30 | 2021-2025 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $170.04 | 2022-2023 | Austedo |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Prenatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.